Danielle Hammond, The University of Texas MD Anderson Cancer Center, Houston, TX, shares the findings of a retrospective analysis of venetoclax-based therapy in patients with chronic myelomonocytic leukemia (CMML), with or without blast transformation (BT). Most of the identified cohort were treated with venetoclax after progressing on hypomethylating agents, after which there is no standard of care. The results showed venetoclax to be effective in CMML and CMML-BT, giving response rates of 59% and 67%, respectively. Mutation testing identified RAS pathway mutations as predictive of worse responses. While effective as a bridging therapy to allogeneic transplant in some patients, the overall duration of response was low in those receiving no subsequent treatment. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.